Abstract
Background:Lactobacillus plantarum PS128 (PS128) is a specific probiotic, known as a psychobiotic, which has been demonstrated to alleviate motor deficits and inhibit neurodegenerative processes in Parkinson's disease (PD)-model mice. We hypothesize that it may also be beneficial to patients with PD based on the possible mechanism via the microbiome-gut-brain axis.
Methods: This is an open-label, single-arm, baseline-controlled trial. The eligible participants were scheduled to take 60 billion colony-forming units of PS128 once per night for 12 weeks. Clinical assessments were conducted using the Unified Parkinson's Disease Rating Scale (UPDRS), modified Hoehn and Yahr scale, and change in patient “ON-OFF” diary recording as primary outcome measures. The non-motor symptoms questionnaire, Beck depression inventory-II, patient assessment of constipation symptom, 39-item Parkinson's Disease Questionnaire (PDQ-39), and Patient Global Impression of Change (PGI-C) were assessed as secondary outcome measures.
Results: Twenty-five eligible patients (32% women) completed the study. The mean age was 61.84 ± 5.74 years (range, 52–72), mean disease duration was 10.12 ± 2.3 years (range, 5–14), and levodopa equivalent daily dosage was 1063.4 ± 209.5 mg/daily (range, 675–1,560). All patients remained on the same dosage of anti-parkinsonian and other drugs throughout the study. After 12 weeks of PS128 supplementation, the UPDRS motor scores improved significantly in both the OFF and ON states (p = 0.004 and p = 0.007, respectively). In addition, PS128 intervention significantly improved the duration of the ON period and OFF period as well as PDQ-39 values. However, no obvious effect of PS128 on non-motor symptoms of patients with PD was observed. Notably, the PGI-C scores improved in 17 patients (68%). PS128 intervention was also found to significantly reduce plasma myeloperoxidase and urine creatinine levels.
Conclusion: The present study demonstrated that PS128 supplementation for 12 weeks with constant anti-parkinsonian medication improved the UPDRS motor score and quality of life of PD patients. We suggest that PS128 could serve as a therapeutic adjuvant for the treatment of PD. In the future, placebo-controlled studies are needed to further support the efficacy of PS128 supplementation.
Clinical Trial Registration:https://clinicaltrials.gov/, identifier: NCT04389762.
Introduction
Parkinson's disease (PD) is a neurodegenerative disorder associated with motor and non-motor symptoms (1). The prevalence of PD increases with age, and PD affects 1% of the population over 60 years (2). Dopaminergic medications are effective treatments for PD patients. However, there are several side effects of dopaminergic drugs such as motor fluctuations, dyskinesia, and other psychological behaviors (3). The key pathological features of PD include a selective loss of dopamine-producing neurons in the substantia nigra, a region in the midbrain, and the presence of Lewy bodies, which consist primarily of misfolded α-synuclein (4). For decades, scientists focused on the substantia nigra to study how the disease process actually begins; however, accumulating evidence suggests that in some patients, PD originates in the gut (5). Clinically, the non-motor symptoms, including gastrointestinal manifestations, often appear years before the motor symptoms and aggregates of α-synuclein have been found in enteric nerves of patients with PD (6). Enteroendocrine cells (EECs), which are sensory epithelial cells of the gut, are able to express α-synuclein and synapse with enteric nerves (7); patients undergoing vagotomy, a surgical procedure that removes all or part of the vagus nerve, have a reduced risk of developing PD (8). Furthermore, gut dysbiosis has been suggested to be a contributing factor to the pathophysiology of PD (1, 9). These findings also indicate possible uses of food-based treatments, including probiotics, for PD (10).
Probiotics are defined as live microorganisms, which when administered in adequate amounts confer a health benefit on the host (11). Specific probiotic strains, also known as psychobiotics, have been shown to confer beneficial effects on the brain via the microbiome-gut-brain axis (12, 13). Previous studies have reported a novel psychobiotic strain, Lactobacillus plantarum PS128 (PS128), which ameliorated abnormal behaviors and regulates both dopaminergic and serotonergic signaling in the brain of mice (14, 15). Oral administration of PS128 also modulated peripheral serotonin levels in rats (16), suggesting an interaction between PS128 and serotonin-producing EECs, which account for ~90% of the body's serotonin levels (17). Furthermore, PS128 ingestion alleviated motor deficits, nigrostriatal dopaminergic neuronal cell death, and striatal dopamine reduction in a PD mouse model (18), thus providing an insight into the use of PS128 as a potential treatment or add-on treatment alternative for patients with PD.
In previous clinical studies, PS128 has been reported to ameliorate behaviors in children with autism spectrum disorder (19) and improve physiological adaptation and performance in triathletes (20, 21). In this study, we aimed to investigate the add-on effect of PS128 supplementation for 12 weeks in patients with PD with an OFF period (the medication is not working well, and symptoms of PD have temporarily reappeared) longer than 3 h a day. Motor and non-motor symptoms, self-reported health status and quality of life, and metabolic parameters in the blood and urine of the patients were measured before and after PS128 intervention and were compared to each other.
Methods
Participants and Study Design
The present study was conducted as an open-label, single-arm, baseline-controlled trial to evaluate the effects of PS128 supplementation on PD. The inclusion criteria were: (i) diagnosis of idiopathic PD, (ii) according to the record of ON/OFF diary for 3 consecutive days, the patient's daily OFF periods were more than 3 h a day, and (iii) age 40–80 years. The exclusion criteria were: (i) use of antibiotics within the preceding 1 month, (ii) use of other probiotic products (in the form of sachet, capsule, or tablet) within the preceding 2 weeks, (iii) previous surgery on the liver, bladder, or gastrointestinal tract, (iv) history of inflammatory bowel disease or cancer, (v) known allergy to probiotics, (vi) comorbid dementia (Mini-Mental State Examination [MMSE] score ≤ 26) or major depression (Beck Depression Inventory-II [BDI-II] score ≥ 29), (vii) history of deep brain stimulation, and (viii) ongoing artificial enteral or intravenous nutrition. In this study, 26 eligible subjects were enrolled, 25 completed the trial, and 1 dropped out due to personal reason (withdrew consent) (Figure 1). At the first screening visit, the principal investigator (PI) would arrange the interview with subjects to ensure whether he/she had experienced any differences in his/her symptoms between levodopa doses. For some patients, ON/OFF fluctuations were somewhat predictable but the symptoms experienced each time still varied. Once the PI confirmed that the subjects understood what ON/OFF meant and felt like, the PI would teach them how to fill out a symptom diary. Subjects had the chance to practice for 3 days, and once the diary was recorded correctly and properly, a new diary would be given to the subjects to record for 7 days. All patients were administered two capsules containing PS128 (30 billion colony-forming units per capsule) daily for 12 weeks. PS128 is a food supplement approved by the Taiwan Food and Drug Administration, and toxicological assessments have indicated that PS128 is safe for human supplementation (22). Compliance rate was assessed by counting the remaining capsules.
Figure 1
Study flow diagram.
The study design followed the guidelines laid down in the Declaration of Helsinki and all procedures were conducted by trained testers at the Professor Lu Neurological Clinic, with approval by the Institutional Review Board of Antai Medical Care Cooperation, Antai Tian-Sheng Memorial Hospital (TSMH IRB No./Protocol No: 18-130-A). Written informed consent was obtained from all subjects.
Assessment of Outcomes
In this study, the primary measurements were the Unified Parkinson's Disease Rating Scale part III (UPDRS-III) motor scores and changes in patient's “ON-OFF” diary recordings, and modified Hoehn and Yahr scale (mHYS). The secondary measurements were the 39-item Parkinson's Disease Questionnaire (PDQ-39), Non-Motor Symptoms Scale (NMSS), BDI-II, patient assessment of constipation symptoms (PAC-SYM), Patient Global Impression of Change (PGI-C), and other metabolic profiles. All clinical assessments were performed after 12 h of overnight withdrawal from antiparkinsonian medications (24 h of withdrawal was needed if the participants were taking prolonged release dopaminergic agonists). Therefore, UPDRS-III and mHYS were scored in the OFF state the next morning as well as the metabolic profiles. Then, the medications were self-administered by each patient before the secondary measurements. The UPDRS, mHYS, PDQ-39, NMSS, BDI-II, PAC-SYM, and PGI-C were scored 40–60 min later in the patients' best ON state. For safety assessment, physical and neurological examinations were performed to evaluate the overall health of the subjects at weeks 0 and 12. In addition, all subjects were actively monitored for the occurrence of adverse events by telephone at least once per week.
Biochemical Measurements
A blood sample of 15 mL and a urine sample of 10 mL were collected at weeks 0 and 12. The serum high-sensitivity C-reactive protein level was determined by turbidimetric immunoassay (23). The plasma myeloperoxidase (MPO) and urinary 8-hydroxy-2'-deoxyguanosine were measured by enzyme-linked immunosorbent assay. The plasma glutathione peroxidase and total antioxidant capacity were measured by Ransel test kits (Randox Laboratories Ltd., UK) and ferric-reducing ability (24), respectively. The urinary creatinine (CRE) level was determined by MeDiPro creatinine test. All procedures were performed according to the manufacturer's instructions.
Statistical Methods
All statistical analyses were analyzed using SPSS software (Version 22.0. Armonk, NY: IBM Corp.). Descriptive statistics were reported as the mean ± standard deviation (SD). The sign rank test was applied to the ordinal scale when a significant difference was detected. This test was applied to compare measures of total UPDRS, UPDRS-I, UPDRS-II, UPDRS-III, UPDRS-IV, tremor subscores, rigidity subscores, akinesia subscores, postural instability gait disorder (PIGD) subscores, mHYS, diary recordings, PDQ-39, BDI-II, and PAC-SYM between baseline (V0) and post-12 weeks (V1). The calculation of effect size is (Chohn's d) = mean of change/SD. The chi-square test applied to the nominal scale when a significant difference was detected of NMSS. The differences of metabolic parameters between baseline and probiotics intervention were determined by paired student t-test. The data were reported as mean ± SDs. Statistical significance was determined as p < 0.05.
Results
Baseline Characteristics
Table 1 presents the clinical and baseline demographic data of the patients. As shown in Figure 1, 25 eligible participants (eight female participants) completed the study. The age of subjects was 61.84 ± 5.74 years (range: 52–72 years), and the age at onset was 51.72 ± 6.59 years (range: 40–65 years). The duration of disease was 10.12 ± 2.3 years (range: 5–14 years). The MMSE score was 28.84 ± 1.68 (range: 25–30) and their levodopa equivalent daily dosage was 1063.4 ± 209.5 mg/daily (range: 675–1,560 mg/daily). All participants remained on the same dosage of anti-parkinsonian and other drugs throughout the study. All tested capsules were used by the patients during the intervention leading to a high compliance rate in this study.
Table 1
| Variables | Mean (N = 25) | Range |
|---|---|---|
| Gender | Female/Male = 8/17 | – |
| Age, years | 61.84 ± 5.74 | 52–72 |
| Age at onset, years | 51.72 ± 6.59 | 40–65 |
| Duration of disease, years | 10.12 ± 2.3 | 5–14 |
| Height, cm | 162.54 ± 7.29 | 147–184 |
| Weight, kg | 59.38 ± 7.78 | 47.5–79.5 |
| Body mass index | 22.49 ± 2.64 | 18.1–28.85 |
| Education, years | 12.86 ± 4.13 | 6–20 |
| MMSE | 28.84 ± 1.68 | 25–30 |
| LEDD, mg/daily | 1063.4 ± 209.5 | 675–1,560 |
Demographic characteristics of the patients with PD.
Mean ± SD; MMSE, Mini-Mental State Examination; LEDD, Levodopa equivalent daily dosage.
Primary Outcomes
As shown in Table 2, in the OFF state, administration of PS128 significantly decreased UPDRS motor scores (−3.08 ± 4.41, p = 0.004) and akinesia subscores (−1.96 ± 3.01, p = 0.012). In addition, a trend toward a greater reduction in rigidity subscores (−0.60 ± 1.35, p = 0.057) was observed after PS128 intervention. However, PS128 supplementation did not indicate any significant impact on tremor, rigidity, PIGD subscores, or mHYS. In the ON state, PS128 significantly reduced UPDRS motor scores (−2.56 ± 5.36, p = 0.007) and total UPDRS scores (−3.76 ± 6.04, p = 0.003), while the other scores did not improve. As shown in Table 3, PS128 intervention not only significantly reduced the duration of the OFF period (−0.80 ± 1.85, p = 0.04), but also significantly increased the duration of the ON period (0.84 ± 1.86, p = 0.031).
Table 2
| Outcomes | Baseline (V0) | Range | Post-12 weeks (V1) | Range | P | Change (V1-V0) | ES |
|---|---|---|---|---|---|---|---|
| OFF-state | |||||||
| UPDRS-III | 27.16 ± 7.11 (26) | 14–46 | 24.08 ± 8.2 (24) | 10–42 | 0.004 | −3.08 ± 4.41 | 0.699 |
| Tremor subscores | 2.2 ± 2.27 (2) | 0–8 | 2.04 ± 2.01 (1) | 0–7 | 1.000 | −0.16 ± 1.21 | 0.132 |
| Rigidity subscores | 5.48 ± 3 (6) | 1–10 | 4.88 ± 3.06 (5) | 0–10 | 0.057 | −0.60 ± 1.35 | 0.443 |
| Akinesia subscores | 11.64 ± 3.4 (11) | 4–20 | 9.68 ± 4.03 (10) | 3–17 | 0.012 | −1.96 ± 3.01 | 0.652 |
| PIGD subscores | 1.88 ± 0.97 (2) | 0–4 | 1.68 ± 1.14 (1) | 0–4 | 0.267 | −0.2 ± 0.71 | 0.283 |
| mHYS | 2.4 ± 0.38 (2.5) | 2–3 | 2.3 ± 0.38 (2) | 2–3 | 0.125 | −0.1 ± 0.25 | 0.400 |
| ON-state | |||||||
| UPDRS-I | 2.64 ± 1.75 (2) | 0–7 | 2.48 ± 1.64 (2) | 1–7 | 0.607 | −0.16 ± 1.03 | 0.156 |
| UPDRS-II | 9.7 ± 4.27 (10) | 2–16 | 8.8 ± 3.8 (10) | 2–15 | 0.383 | −0.92 ± 2.89 | 0.319 |
| UPDRS-III | 17.56 ± 6.92 (16) | 8–33 | 15 ± 7.76 (15) | 4–36 | 0.007 | −2.56 ± 5.36 | 0.477 |
| UPDRS-IV | 3.08 ± 1.19 (3) | 2–6 | 2.96 ± 1.02 (3) | 2–6 | 1.000 | −0.12 ± 1.39 | 0.086 |
| Total UPDRS | 33 ± 10.65 (30) | 15–51 | 29.24 ± 10.26 (30) | 12–53 | 0.003 | −3.76 ± 6.04 | 0.623 |
| Tremor subscores | 1.08 ± 1.19 (1) | 0–4 | 0.72 ± 0.84 (1) | 0–3 | 0.118 | −0.36 ± 0.99 | 0.362 |
| Rigidity subscores | 3.48 ± 2.28 (4) | 0–8 | 3 ± 2.58 (3) | 0–10 | 0.302 | −0.48 ± 1.56 | 0.308 |
| Akinesia subscores | 8.68 ± 3.42 (8) | 4–21 | 7.36 ± 3.44 (7) | 1–14 | 0.078 | −1.32 ± 3.15 | 0.420 |
| PIGD subscores | 0.6 ± 0.91 (0) | 0–3 | 0.44 ± 0.92 (0) | 0–3 | 0.453 | −0.16 ± 0.62 | 0.256 |
| mHYS | 2.12 ± 0.3 (2) | 2–3 | 2.1 ± 0.32 (2) | 1.5–3 | 1.000 | −0.02 ± 0.18 | 0.114 |
The OFF- and ON-states of the unified Parkinson's disease rating scale of patients with PD at baseline and after 12 weeks of intervention.
Change in negative value indicates improvement. Mean ± SD (Medium); p: signed rank test, α = 0.05, 2-tailed; ES: 0.2 small effect, 0.5 medium effect, 0.8 large effect; Tremor subscores: items 20-21 (tremor at rest, action or postural tremor of hands); Rigidity subscores: item 22 (rigidity); Akinesia subscores: items 23–26 (finger taps, hand movements, rapid alternating movements of the hands, and leg agility); PIGD subscores: items 29–30 (gait, postural stability).
ES, effect size; UPDRS, unified Parkinson's disease rating scale; mHYS, modified Hoehn and Yahr scale.
Table 3
| Hours/per day | Baseline (V0) | Range | Post-12 weeks (V1) | Range | p | Change (V1-V0) | ES |
|---|---|---|---|---|---|---|---|
| OFF period | 6.52 ± 1.66 (6.33) | 3.8–11 | 5.72 ± 2.64 (5.67) | 0–10.33 | 0.04 | −0.80 ± 1.85 | 0.43 |
| Moderate | 1.08 ± 1.71 (0) | 0–5.33 | 0.86 ± 1.50 (0) | 0–4.83 | 0.754 | −0.22 ± 1.29 | 0.17 |
| Mild | 5.43 ± 2.39 (5.33) | 0.17–11 | 4.86 ± 2.80 (5.67) | 0–10.33 | 0.09 | −0.57 ± 1.47 | 0.39 |
| ON period | 9.92 ± 1.76 (10.33) | 5.17–12.5 | 10.76 ± 2.29 (11) | 4.67–15.5 | 0.031 | 0.84 ± 1.86 | −0.45 |
| Sleep | 7.56 ± 1.73 (7.83) | 4.67–10.83 | 7.51 ± 1.68 (7.17) | 4.17–10.70 | 0.552 | −0.04 ± 0.78 | 0.05 |
Diary recordings of ON and OFF durations in patients with PD at baseline and after 12 weeks of intervention.
Change in negative value indicates improvement: off period; change in positive value indicates improvement: on period.
Mean ± SD (Medium); p: Wilcoxon signed rank test, α = 0.05, 2-tailed; ES: 0.2 small effect, 0.5 medium effect, 0.8 large effect.
ES, effect size.
Secondary Outcomes
Comparing PDQ-39 values of patients with PD, the single index score significantly reduced after the 12-week intervention (−5.68 ± 8.55, p = 0.031) (Table 4), as well as mobility (−6.1 ± 12.73, p = 0.049), activities of daily living (−6.5 ± 11.85, p = 0.039), stigma (−8.75 ± 16.73, p = 0.039), and cognition (−6.75 ± 11.11, p = 0.021) dimensions. After 12 weeks of PS128 administration, the NMSS of none of the patients with PD improved significantly (Table 5). Most of the patients with PD expressed satisfaction with the PS128 intervention, and the PGI-C scores improved in 17 patients (68%) (Table 6). In addition, no adverse events related to PS128 intervention were found by the safety assessment.
Table 4
| PDQ-39 | Baseline (V0) | Range | Post-12 weeks (V1) | Range | p | Change (V1-V0) | ES |
|---|---|---|---|---|---|---|---|
| Single index | 19.86 ± 9.6 | 3.39–40.42 | 14.18 ± 8.61 | 3.44–40.42 | 0.031 | −5.68 ± 8.55 | 0.664 |
| Mobility | 19.2 ± 12.33 | 2.5–45 | 13.1 ± 13.43 | 0–62.5 | 0.049 | −6.1 ± 12.73 | 0.479 |
| Activities of daily living | 17.83 ± 15.24 | 0–54.17 | 11.34 ± 8.8 | 0–29.17 | 0.039 | −6.5 ± 11.85 | 0.548 |
| Emotional well-being | 19.67 ± 16.07 | 0–75 | 13.67 ± 16.65 | 0–75 | 0.077 | −6 ± 10.96 | 0.547 |
| Stigma | 23.5 ± 17.33 | 0–75 | 14.75 ± 13.12 | 0–43.75 | 0.039 | −8.75 ± 16.73 | 0.523 |
| Social support | 7.67 ± 7.95 | 0–25 | 6 ± 8.51 | 0–25 | 0.344 | −1.67 ± 5.89 | 0.283 |
| Cognitions | 28 ± 17.96 | 0–62.5 | 21.25 ± 16.54 | 0–62.5 | 0.021 | −6.75 ± 11.11 | 0.608 |
| Communication | 21 ± 16.69 | 0–58.33 | 15.33 ± 12.88 | 0–50 | 0.146 | −5.67 ± 13.55 | 0.418 |
| Bodily discomfort | 22 ± 16.3 | 0–66.67 | 18 ± 12.43 | 0–41.67 | 1.000 | −4 ± 15.98 | 0.250 |
The 39-item Parkinson's disease questionnaire of patients with PD at baseline and after 12 weeks of intervention.
Change in negative value indicates improvement. Mean ± SD; p: signed rank test, α = 0.05, 2-tailed; ES: 0.2 small effect, 0.5 medium effect, 0.8 large effect.
PDQ-39, 39-item Parkinson's disease questionnaire; ES, effect size.
Table 5
| Outcomes | Baseline (V0) | Post-12 weeks (V1) | p | ||
|---|---|---|---|---|---|
| Total NMSS | 6.84 ± 4.65 (5) | Range 0–18 | 6.28 ± 4.35 (6) | Range 0–16 | 0.115 |
| NMS Domain, % | No | Yes | No | Yes | p' |
| Gastrointestinal tract | 24 | 76 | 20 | 80 | 0.625 |
| Urinary tract | 60 | 40 | 48 | 52 | 0.063 |
| Sexual function | 48 | 52 | 48 | 52 | 1 |
| Cardiovascular | 80 | 20 | 80 | 20 | 1 |
| Cognitive function | 44 | 56 | 44 | 56 | 1 |
| Mood disorders | 68 | 32 | 80 | 20 | 1 |
| Sleep disorders | 68 | 32 | 68 | 32 | 0.727 |
| Impulse control disorders | 100 | 0 | 100 | 0 | NA |
| Others | 48 | 52 | 48 | 52 | 1 |
| BDI-II | 8.6 ± 6.4 (7) | 1–25 | 7.64 ± 7.08 (5) | 0–34 | 1.000 |
| PAC-SYM | 7.8 ± 4.92 (8) | 0–17 | 6.32 ± 5.1 (5) | 0–20 | 0.108 |
The non-motor symptoms of patients with PD at baseline and after 12 weeks of intervention.
Mean ± SD (Medium); p', Chi square; NMSS, Non-Motor Symptoms Scale; BDI-II, Beck Depression Inventory-II; PAC-SYM, patient assessment of constipation symptoms.
Table 6
| PGI-C at V1 (post 12-weeks) | No. | % | Accumulative, % |
|---|---|---|---|
| Very much improved | 1 | 4 | 4 |
| Much improved | 4 | 16 | 20 |
| Minimally improved | 12 | 48 | 68 |
| No change | 7 | 28 | 96 |
| Minimally worse | 1 | 4 | 100 |
| Much worse | 0 | 0 | 100 |
| Very much worse | 0 | 0 | 100 |
The PS128 intervention improves patient global impression of change scores.
PGI-C, patient global impression of change.
Changes in Metabolic Parameters
Consumption of PS128 significantly reduced the level of plasma MPO (p < 0.01) (Figure 2). PS128 intervention also decreased the urinary CRE levels (p = 0.03) (Figure 2). There was no statistical difference in other metabolic parameters after PS128 intervention.
Figure 2
The effect of PS128 intervention on metabolic parameters of (A) hs-CRP, (B) MPO, (C) TAC, (D) GPx, (E) 8-OHdG, and (F) CRE. *p < 0.05; **p < 0.01 as compared to baseline (V0). Mean ± SD; P, Obtained from paired t test; hs-CRP, high-sensitivity C-reactive protein; MPO, myeloperoxidase; TAC, total antioxidant capacity; GPx, glutathione peroxidase; 8-OHdG, 8-hydroxy-2'-deoxyguanosine; CRE, creatinine.
Discussion
To our knowledge, this study is the first to report that a single strain probiotic can improve the UPDRS motor score of patients with PD in both the OFF and ON states. The UPDRS motor score decreased by 3.08 (11.3% improvement, 3.08/27.16) in the OFF state and 2.56 (14.6% improvement, 2.56/17.56) in the ON state (Table 2). Akinesia is related to dysfunction of automaticity and can affect almost all activities of daily life (25, 26). Thus, akinesia is one of most distressing motor disturbances experienced by patients with PD. In this study, the akinesia subscore decreased by 1.96 (16.8% improvement, 1.96/11.64) in the OFF state (Table 2). In agreement with the results from the akinesia subscore in the OFF state (Table 2), the activities of daily living dimension of the PDQ-39 (Table 4) was significantly improved by PS128 intervention. The PDQ-39 value suggested that the quality of life of patients with PD was less affected by disability. Moreover, the activities of daily living dimension of the PDQ-39 indicates the limitations in activities of daily living such as washing oneself, dressing oneself, and writing. In addition, the diary recording data suggested the add-on effect of PS128 in patients with PD by prolonging the ON period and decreasing the OFF period (Table 3). The above data suggested that PS128 intervention had add-on effects by improving the quality of life of patients with PD. The evidence for the effects of probiotics on ameliorating PD remains limited. The majority of probiotics research on patients with PD has been performed using a mixture of probiotics and have investigated the effect of gastrointestinal functions. It has been found that the consumption of a mixture of probiotics resulted in a reduced score on the UPDRS (27). Another clinical study reported that supplementation of a mixture of probiotics ameliorated inflammation in patients with PD (28). In addition, three studies demonstrated that treatment with a mixture of probiotics or fermented milk containing probiotics resulted in improved abdominal pain, bloating, and constipation, respectively (29–31).
MPO is a peroxidase enzyme that can produce reactive oxygen and nitrogen species (32). It has been reported that ablation of MPO can reduce neurodegeneration in PD-model mice (33). Recently, Makia et al. reported that MPO plays a crucial role in the aggregation of α-synuclein and deterioration of motor impairment (34). In addition, several studies have suggested that MPO inhibitors can be therapeutic in neurodegenerative diseases (35–38). It has been reported that PS128 intervention not only significantly improves motor impairment but can also restore the survival of dopaminergic neurons in the substantia nigra and striatum of PD-model mice (18). The immune system plays an important role in the pathophysiology of PD (39). In comparison with healthy subjects, hyperactivation of microglial cells and induction of microglia-derived cytokines were found in the patients with PD (40–42). Notably, administration of PS128 ameliorated neuroinflammation, increased antioxidant activity, and enhanced levels of neurotrophic factor in PD-model mice (18).
More than 30% of patients with PD suffer from gastrointestinal symptoms (43). Gastrointestinal problems such as constipation and delayed gastric emptying are frequently observed in patients with PD (44). However, we did not observe a significant improvement in NMSS and PAC-SYM in patients with PD after a 12-week intervention with PS128 (Table 5). It is possible that all subjects remained on their gastrointestinal-related drugs, including magnesium oxide, bisacodyl, and sennoside A+B calcium, throughout the study (Supplementary Table 1). The effect of PS128 on gastrointestinal symptoms requires further study.
Emerging evidence shows that misfolded α-synuclein seems to appear in the EECs and enteric nerves first, and then in the brain (45–47). Experimentally, α-synuclein can be spread from the gut to brain via the vagus nerve, resulting in the loss of dopaminergic neurons in the substantia nigra (6, 48). Besides, a previous study has reported that oral administration of PS128 to rats increased the level of peripheral serotonin produced by EECs (16, 17), suggesting that there is an interaction between PS128 and EECs. Therefore, it is possible that PS128 regulates the production of α-synuclein in the EECs and enteric nerves, thereby alleviating the progression of PD, and the possibility remains to be studied.
There are a few limitations to the present study. Firstly, this study is an open-label trial rather than placebo-controlled, blinded, or randomized study. Therefore, follow-up large-scale, randomized controlled studies are needed to determine the efficacy of PS128 in patients with PD at different stages. Secondly, the effect of PS128 on the gut microbiome was not evaluated in this pilot study. Emerging evidence has demonstrated that the gut microbiome plays an important role in development and maintenance of human physiology (1, 49, 50). Recently, alteration of the gut microbiome composition in patients with PD has been found (51–53). These changes are considered to induce the loss of dopaminergic neurons by triggering inflammation, reduce levels of neuroprotective factors, and produce neurotoxins into the systemic circulation (1). However, whether a specific microbial species regulates the pathophysiology of PD remains a controversial issue. Whether PS128 affects the symptoms of PD via modulation of the gut microbiome warrants further investigation.
Conclusion
In summary, the present study demonstrated that supplementation with PS128 for 12 weeks significantly improved the UPDRS motor scores in both the OFF and ON states, the duration of the ON period, and the quality of life of patients with PD. This pilot study suggests that PS128 could be considered as a therapeutic adjuvant for the treatment of PD. Further studies are required to determine the role of PS128 on inflammatory/metabolic parameters and the gut microbiome in regulating PD.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
Ethics statement
The studies involving human participants were reviewed and approved by Institutional Review Board of Antai Medical Care Cooperation, Antai Tian-Sheng Memorial Hospital (TSMH IRB No./Protocol No: 18-130-A). The patients/participants provided their written informed consent to participate in this study.
Author contributions
H-CC and Y-SK designed the study, performed all the clinical assessments, analyzed, and interpreted data. C-CC and Y-HW recruited the patients and edited the manuscript. H-CC wrote the manuscript. Y-CT critically reviewed the manuscript but was not involved in any data collection or analysis. C-SL supervised the study and critically edited the manuscript. All authors listed have contributed substantially to the work as noted and agreed to submit the manuscript.
Acknowledgments
The authors thank all the subjects and their families that participated in this study. Bened Biomedical Co., Ltd. provided PS128 capsules without compensation.
Conflict of interest
Y-CT owns stock of Bened Biomedical Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2021.650053/full#supplementary-material
References
1.
ElfilMKamelSKandilMKooBBSchaeferSM. Implications of the gut microbiome in Parkinson's disease. Mov Disord. (2020) 35:921–33. 10.1002/mds.28004
2.
TysnesOBStorsteinA. Epidemiology of Parkinson's disease. J Neural Transm. (2017) 124:901–5. 10.1007/s00702-017-1686-y
3.
TranTNVoTNNFreiKTruongDD. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm. (2018) 125:1109–17. 10.1007/s00702-018-1900-6
4.
ZhangGXiaYWanFMaKGuoXKouLet al. New perspectives on roles of alpha-synuclein in Parkinson's disease. Front Aging Neurosci. (2018) 10:370. 10.3389/fnagi.2018.00370
5.
BorghammerPVan Den BergeN. Brain-first versus gut-first parkinson's disease: a hypothesis. J Parkinsons Dis. (2019) 9:S281–95. 10.3233/JPD-191721
6.
LiddleRA. Parkinson's disease from the gut. Brain Res. (2018) 1693(Pt B):201–6. 10.1016/j.brainres.2018.01.010
7.
ChandraRHinikerAKuoYMNussbaumRLLiddleRA. alpha-Synuclein in gut endocrine cells and its implications for Parkinson's disease. JCI Insight. (2017) 2:e92295. 10.1172/jci.insight.92295
8.
LiuBFangFPedersenNLTillanderALudvigssonJFEkbomAet al. Vagotomy and Parkinson disease: a Swedish register-based matched-cohort study. Neurology. (2017) 88:1996–2002. 10.1212/WNL.0000000000003961
9.
HaikalCChenQQLiJY. Microbiome changes: an indicator of Parkinson's disease?Transl Neurodegener. (2019) 8:38. 10.1186/s40035-019-0175-7
10.
GazeraniP. Probiotics for Parkinson's disease. Int J Mol Sci. (2019) 20:4121. 10.3390/ijms20174121
11.
HillCGuarnerFReidGGibsonGRMerensteinDJPotBet al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. (2014) 11:506–14. 10.1038/nrgastro.2014.66
12.
Long-SmithCO'RiordanKJClarkeGStantonCDinanTGCryanJF. Microbiota-gut-brain axis: new therapeutic opportunities. Annu Rev Pharmacol Toxicol. (2020) 60:477–502. 10.1146/annurev-pharmtox-010919-023628
13.
DinanTGStantonCCryanJF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry. (2013) 74:720–6. 10.1016/j.biopsych.2013.05.001
14.
LiuWHChuangHLHuangYTWuCCChouGTWangSet al. Alteration of behavior and monoamine levels attributable to Lactobacillus plantarum PS128 in germ-free mice. Behav Brain Res. (2016) 298(Pt B):202–9. 10.1016/j.bbr.2015.10.046
15.
LiuYWLiuWHWuCCJuanYCWuYCTsaiHPet al. Psychotropic effects of Lactobacillus plantarum PS128 in early life-stressed and naive adult mice. Brain Res. (2016) 1631:1–12. 10.1016/j.brainres.2015.11.018
16.
LiaoJFChengYFLiSWLeeWTHsuCCWuCCet al. Lactobacillus plantarum PS128 ameliorates 2,5-Dimethoxy-4-iodoamphetamine-induced tic-like behaviors via its influences on the microbiota-gut-brain-axis. Brain Res Bull. (2019) 153:59–73. 10.1016/j.brainresbull.2019.07.027
17.
BertacciniG. Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastro-intestinal tract in the rat. J Physiol. (1960) 153:239–49. 10.1113/jphysiol.1960.sp006532
18.
LiaoJFChengYFYouSTKuoWCHuangCWChiouJJet al. Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson's disease. Brain Behav Immun. (2020) 90:26–46. 10.1016/j.bbi.2020.07.036
19.
LiuYWLiongMTChungYEHuangHYPengWSChengYFet al. Effects of Lactobacillus plantarum PS128 on children with Autism Spectrum Disorder in Taiwan: a randomized, double-blind, placebo-controlled trial. Nutrients. (2019) 11:820. 10.3390/nu11040820
20.
HuangWCWeiCCHuangCCChenWLHuangHY. The beneficial effects of Lactobacillus plantarum PS128 on high-intensity, exercise-induced oxidative stress, inflammation, and performance in Triathletes. Nutrients. (2019) 11:353. 10.3390/nu11020353
21.
HuangWCPanCHWeiCCHuangHY. Lactobacillus plantarum PS128 Improves physiological adaptation and performance in triathletes through gut microbiota modulation. Nutrients. (2020) 12:2315. 10.3390/nu12082315
22.
LiaoPLWuCCChenTYTsaiYCPengWSYangDJet al. Toxicity studies of Lactobacillus plantarum PS128TM isolated from spontaneously fermented mustard greens. Foods. (2019) 8:668. 10.3390/foods8120668
23.
OtsujiSShibataHUmedaM. Turbidimetric immunoassay of serum C-reactive protein. Clin Chem. (1982) 28:2121–4. 10.1093/clinchem/28.10.2121
24.
BenzieIFStrainJJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Anal Biochem. (1996) 239:70–6. 10.1006/abio.1996.0292
25.
MarsdenCD. Slowness of movement in Parkinson's disease. Mov Disord. (1989) 4(Suppl 1):S26–37. 10.1002/mds.870040505
26.
HallettM. Bradykinesia: why do Parkinson's patients have it and what trouble does it cause?Mov Disord. (2011) 26:1579–81. 10.1002/mds.23730
27.
TamtajiORTaghizadehMDaneshvar KakhakiRKouchakiEBahmaniFBorzabadiS. Clinical and metabolic response to probiotic administration in people with Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. (2019) 38:1031–5. 10.1016/j.clnu.2018.05.018
28.
BorzabadiSOryanSEidiAAghadavodEDaneshvar KakhakiRTamtajiOR. The effects of probiotic supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson's disease: a randomized, double-blind, placebocontrolled trial. Arch Iran Med. (2018) 21:289–95.
29.
GeorgescuDAncusaOEGeorgescuLAIonitaIReiszD. Nonmotor gastrointestinal disorders in older patients with Parkinson's disease: is there hope?Clin Interv Aging. (2016) 11:1601–8. 10.2147/CIA.S106284
30.
BarichellaMPacchettiCBolliriCCassaniEIorioLPusaniCet al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT. Neurology. (2016) 87:1274–80. 10.1212/WNL.0000000000003127
31.
CassaniEPriviteraGPezzoliGPusaniCMadioCIorioLet al. Use of probiotics for the treatment of constipation in Parkinson's disease patients. Minerva Gastroenterol Dietol. (2011) 57:117–21.
32.
MalleEBuchTGroneHJ. Myeloperoxidase in kidney disease. Kidney Int. (2003) 64:1956–67. 10.1046/j.1523-1755.2003.00336.x
33.
ChoiDKPennathurSPerierCTieuKTeismannPWuDCet al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci. (2005) 25:6594–600. 10.1523/JNEUROSCI.0970-05.2005
34.
MakiRAHolzerMMotamedchabokiKMalleEMasliahEMarscheGet al. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-alpha-synuclein-A53T mouse model, correlating with increased nitration and aggregation of alpha-synuclein and exacerbation of motor impairment. Free Radic Biol Med. (2019) 141:115–40. 10.1016/j.freeradbiomed.2019.05.033
35.
JucaiteASvenningssonPRinneJOCselenyiZVarnasKJohnstromPet al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. (2015) 138(Pt 9):2687–700. 10.1093/brain/awv184
36.
ZhangHRayAMillerNMHartwigDPritchardKADittelBN. Inhibition of myeloperoxidase at the peak of experimental autoimmune encephalomyelitis restores blood-brain barrier integrity and ameliorates disease severity. J Neurochem. (2016) 136:826–36. 10.1111/jnc.13426
37.
StefanovaNGeorgievskaBErikssonHPoeweWWenningGK. Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model. Neurotox Res. (2012) 21:393–404. 10.1007/s12640-011-9294-3
38.
KaindlstorferCSommerPGeorgievskaBMatherRJKuglerARPoeweWet al. Failure of neuroprotection despite microglial suppression by delayed-start myeloperoxidase inhibition in a model of advanced multiple system atrophy: clinical implications. Neurotox Res. (2015) 28:185–94. 10.1007/s12640-015-9547-7
39.
MosleyRLHutter-SaundersJAStoneDKGendelmanHE. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med. (2012) 2:a009381. 10.1101/cshperspect.a009381
40.
MirzaBHadbergHThomsenPMoosT. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience. (2000) 95:425–32. 10.1016/S0306-4522(99)00455-8
41.
Blum-DegenDMullerTKuhnWGerlachMPrzuntekHRiedererP. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett. (1995) 202:17–20. 10.1016/0304-3940(95)12192-7
42.
MogiMHaradaMNarabayashiHInagakiHMinamiMNagatsuT. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett. (1996) 211:13–6. 10.1016/0304-3940(96)12706-3
43.
PfeifferRF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. (2003) 2:107–16. 10.1016/S1474-4422(03)00307-7
44.
BaronePAntoniniAColosimoCMarconiRMorganteLAvarelloTPet al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. (2009) 24:1641–9. 10.1002/mds.22643
45.
BraakHDel TrediciKRubUde VosRAJansen SteurENBraakE. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. (2003) 24:197–211. 10.1016/S0197-4580(02)00065-9
46.
BraakHDel TrediciK. Neuroanatomy and pathology of sporadic Parkinson's disease. Adv Anat Embryol Cell Biol. (2009) 201:1–119.
47.
CorbilleAGLetournelFKordowerJHLeeJShanesENeunlistMet al. Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies. Acta Neuropathol Commun. (2016) 4:35. 10.1186/s40478-016-0305-8
48.
KimSKwonSHKamTIPanickerNKaruppagounderSSLeeSet al. Transneuronal propagation of pathologic alpha-synuclein from the gut to the brain models parkinson's disease. Neuron. (2019) 103:627–41.e7. 10.1016/j.neuron.2019.05.035
49.
CryanJFO'RiordanKJCowanCSMSandhuKVBastiaanssenTFSBoehmeMet al. The microbiota-gut-brain axis. Physiol Rev. (2019) 99:1877–2013. 10.1152/physrev.00018.2018
50.
CryanJFO'RiordanKJSandhuKPetersonVDinanTG. The gut microbiome in neurological disorders. Lancet Neurol. (2020) 19:179–94. 10.1016/S1474-4422(19)30356-4
51.
KeshavarzianAGreenSJEngenPAVoigtRMNaqibAForsythCBet al. Colonic bacterial composition in Parkinson's disease. Mov Disord. (2015) 30:1351–60. 10.1002/mds.26307
52.
ScheperjansFAhoVPereiraPAKoskinenKPaulinLPekkonenEet al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. (2015) 30:350–8. 10.1002/mds.26069
53.
Heintz-BuschartAPandeyUWickeTSixel-DoringFJanzenASittig-WiegandEet al. The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord. (2018) 33:88–98. 10.1002/mds.27105
Summary
Keywords
Lactobacillus plantarum, PS128, Parkinson's disease, probiotics, psychobiotics
Citation
Lu C-S, Chang H-C, Weng Y-H, Chen C-C, Kuo Y-S and Tsai Y-C (2021) The Add-On Effect of Lactobacillus plantarum PS128 in Patients With Parkinson's Disease: A Pilot Study. Front. Nutr. 8:650053. doi: 10.3389/fnut.2021.650053
Received
25 March 2021
Accepted
04 June 2021
Published
30 June 2021
Volume
8 - 2021
Edited by
David Vauzour, University of East Anglia, United Kingdom
Reviewed by
Janis Rebecca Bedarf, University Hospital Bonn, Germany; Vadivelan R., JSS College of Pharmacy, India
Updates
Copyright
© 2021 Lu, Chang, Weng, Chen, Kuo and Tsai.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ying-Chieh Tsai tsaiyc@ym.edu.twChin-Song Lu bob.cslu@gmail.com
This article was submitted to Nutrition and Brain Health, a section of the journal Frontiers in Nutrition
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.